Suzette Elisabeth Sutherland, MD | |
1959 Ne Pacific St, Seattle, WA 98195-2649 | |
(206) 520-5000 | |
Not Available |
Full Name | Suzette Elisabeth Sutherland |
---|---|
Gender | Female |
Speciality | Urology |
Experience | 27 Years |
Location | 1959 Ne Pacific St, Seattle, Washington |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508854951 | NPI | - | NPPES |
574138600 | Medicaid | MN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | MD60404575 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Washington Medical Ctr | Seattle, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Association Of University Physicians | 0446162697 | 3009 |
News Archive
Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.
Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.
› Verified 8 days ago
Entity Name | The Association Of University Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.
Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Suzette Elisabeth Sutherland, MD Po Box 50095, Seattle, WA 98145-5095 Ph: (206) 520-5700 | Suzette Elisabeth Sutherland, MD 1959 Ne Pacific St, Seattle, WA 98195-2649 Ph: (206) 520-5000 |
News Archive
Heme oxygenase-1 is essential for the growth of blood vessels in the placenta and in establishing blood flow in the umbilical cord. Too little HO-1 can lead to a restriction in the growth of the fetus and even in fetal death and miscarriage. New research published in BioMed Central's open access journal Medical Gas Research has shown that low dose carbon monoxide therapy is able to restore placental function and prevent fetal death in mice, without any detrimental effects.
Computer simulations of disease processes and detailed digital models of our organs could provide more accurate monitoring and outcome measurements for clinical trials, according to research being presented in Sheffield today.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.
Gene therapy preserved vision in a study involving dogs with naturally occurring, late-stage retinitis pigmentosa, according to research funded by the National Eye Institute (NEI), part of the National Institutes of Health. The findings contribute to the groundwork needed to move gene therapy forward into clinical trials for people with the blinding eye disorder, for which there is currently no cure.
› Verified 8 days ago
Dr. Sandra Jane Hadjinian, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St., Seattle, WA 98195 Phone: 206-520-5000 | |
Dr. Steven Han, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 515 Minor Ave, Suite 200, Seattle, WA 98104 Phone: 206-215-2580 Fax: 206-215-2581 | |
John Steele Mullen, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 515 Minor Ave, Suite 200, Seattle, WA 98104 Phone: 206-215-2580 Fax: 206-215-2581 | |
Jeffrey M Mccracken, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 747 Broadway, Seattle, WA 98122 Phone: 206-386-2043 Fax: 206-386-2508 | |
Dr. Carol Collins, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 272 Health Sciences, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-616-3294 | |
Dr. Daniel Warren Smith, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 9709 3rd Ave Ne, Seattle, WA 98115 Phone: 206-860-4944 | |
Tristan Marriner Nicholson, MD, PHD Urology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-520-5000 |